Abstract
Achromobacter spp. are emerging pathogens in CF. Based on intrinsic resistance and the report of multidrug resistant strains, Achromobacter spp. are considered as difficult-to-treat pathogens. Cefiderocol is a novel siderophore cephalosporin that has been infrequently used in the management of Achromobacter infections and for which susceptibility data are lacking. We evaluated the cefiderocol susceptibility of a collection of CF Achromobacter strains encompassing different airway colonization types, species and antimicrobial susceptibility patterns.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Paper Title
Journal
Date
